
Antiulcer Agents

Tomáš Goněc


26.11.2012

Peptic ulceration

□ Mucose degradation



Mechanism of acid secretion



Peptic ulceration


□ multifactorial disease:

- □ increased acid production and enzyme activity
- decreased acid production and enzyme activity
- □ Helicobacter pylori infection
- □ long-term NSAID medication


□ leads to damage of mucose protective layer and ulcer formation

Helicobacter pylori infection

Divergent mucosal and secretory responses to *H. pylori* infection




Long-term NSAID administration



Therapy

- acids and digestives
- □ direct antacids
- indirect antacids
- mucoprotective drugs
- □ drugs for Helicobacter pylori eradication

Mechanism of action



Acids

- □ achlorhydria low or no HCl secretion
- □ increased pH damages mucosa
- □ citric acid, betaine hydrochloride

citric acid

betaine hydrochloride

Digestives

- □ insufficient digestion longer pass through of food gastritis, ulceration risk
- recombinant enzymes:
 - pepsine, pancreatine, trypsine chymotripsine, amylase, lipase

Direct antacids

□ Carbonates:

```
NaHCO<sub>3</sub>,
```

CaCO₃,

MgCO₃

- quick pH increase may lead to increased gastrine levels and excessive HCl secretion
- absorbtion of Mg²⁺, Ca²⁺ and Na⁺ leads to ion dysballance

Direct antacids

Magnesium oxides and hydroxides:

MgO, MgO₂, Mg(OH)₂

- forming MgCl₂ has laxative effect

Direct antacids

Aluminium compounds:

```
AlPO<sub>4</sub>,
Al(OH)<sub>3</sub> (algeldrate),
Al<sub>5</sub>Mg<sub>10</sub>(OH)<sub>31</sub>(SO<sub>4</sub>)<sub>2</sub>.H<sub>2</sub>O (magaldrate)
```

- both antacide and protective effect
- long-term administration of aluminium salts may cause obstipation

Antimuscarinic agents

Pirenzepine

Pirenzepine synthesis

Selective H2 histamine receptor antagonists

SAR of H2 antagonists:



Cimetidine

Cimetidine synthesis

16.2.3

16.2.4

Ranitidine

Ranitidine synthesis

Nizatidine

Nizatidine synthesis

1.
$$HS-CH_2-CH_2-NH_2$$
 CH_3S
 $CH=CH-NO_2$
 CH_3NH
 CH_3
 $CH_$

Famotidine

famotidine

Famotidine synthesis


16.2.11

Proton pump inhibitors

Table 33.10. H⁺/K⁺-ATPase Proton Pump Inhibitors

| Drugs | Trade Name | R ₁ | R ₂ | R ₃ | R ₄ |
|-----------------------------|------------|-------------------|------------------|--|-----------------|
| Omeprazole | Prilosec | OCH ₃ | CH₃ | CH ₃ | CH ₃ |
| Esomeprozole (S-enantiomer) | Nexium | OCH ₃ | CH ₃ | CH ₃ | CH ₃ |
| Lansoprazole | Prevacid | Н | CH ₃ | CH ₂ CF ₃ | Н |
| Rabeprazole | Aciphex | Н | CH ₃ | (CH ₂) ₃ OCH ₃ | Н |
| Pantoprazole | Protonix | OCHF ₂ | OCH ₃ | CH ₃ | Н |

Omeprazole synthesis




Mechanism of action

Mucoprotective agents


□ misoprostol

Mucoprotective agents

- □ alginic acid, pectines (natural drugs)
- □ sucralfate



Sucralfate synthesis



Drugs for Helicobacter pylori eradication

- □ metronidazole
- □ azithromycine, clarithromycine
- □ amoxyciline
- tetracycline
- □ bismuth salts: subcitrate, subsalicylate